Loading clinical trials...
Loading clinical trials...
An Phase2 Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
Patients with Severe Pneumonia caused by SARS-CoV-2 infection are enrolled to the study. Adipose-derived mesenchymal stem cells (AD-MSCs) are administered once a week, total four times intravenously. Safety and efficacy of AD-MSCs are evaluated for 12 weeks after first administer.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Osaka University Hospital
Suita, Osaka, Japan
Start Date
June 15, 2021
Primary Completion Date
May 18, 2023
Completion Date
May 18, 2023
Last Updated
November 18, 2023
15
ACTUAL participants
Mesenchymal stem cell
BIOLOGICAL
Placebo
BIOLOGICAL
Lead Sponsor
Rohto Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions